Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AAA-614 by Novartis for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
AAA-614 is under clinical development by Novartis and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
AAA-614 by Novartis for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
AAA-614 is under clinical development by Novartis and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
AAA-614 by Novartis for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
AAA-614 is under clinical development by Novartis and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...
AAA-614 by Novartis for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
AAA-614 is under clinical development by Novartis and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive...
AAA-614 by Novartis for Non-Small Cell Lung Cancer: Likelihood of Approval
AAA-614 is under clinical development by Novartis and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...